title: Serum IgA, IgG, and IgM concentrations in patients with epilepsy and matched controls: a cohort-based cross-sectional study.
abstract: Conflicting reports have been published on serum immunoglobulin (Ig) concentrations in patients with epilepsy. Serum IgA, IgG, and IgM concentrations were determined in a cohort of 958 patients and in a reference population of 581 subjects. Overall, 8.2% of patients with epilepsy and 1.9% of control subjects had low serum IgA concentrations. Low serum IgA levels were measured in 19.1% of patients currently on phenytoin therapy and in 11.9% of patients who had previously been treated with phenytoin, whereas only 3.8% of patients who had never been on phenytoin therapy had low serum IgA. In multivariate analysis low serum IgA concentrations were associated with phenytoin medication and female gender. No differences in serum IgG and IgM concentrations were observed between patients and control subjects. However, in patients with epilepsy, low serum IgG concentrations were associated with concomitant autoimmune diseases, and low IgM levels with older age at the onset of epilepsy, long duration of epilepsy, and autoimmune diseases. In conclusion, the prevalence of low serum IgA concentrations was increased in patients with epilepsy, but serum IgG and IgM concentrations were similar in patients with epilepsy and reference subjects. The low serum IgA concentrations were associated with phenytoin medication. In addition to current phenytoin medication, previous phenytoin therapy also was associated with low serum IgA concentrations. This implies that phenytoin medication may have permanent immunological effects in some patients.
authors.affiliation: Department of Neurology, Seinäjoki Central Hospital, Hanneksenrinne 7, Seinäjoki, FIN-60220, Finland. jouni.ranua@netikka.fi
authors.forename: Jouni
authors.initials: J
authors.lastname: Ranua
authors.forename: Katja
authors.initials: K
authors.lastname: Luoma
authors.forename: Anssi
authors.initials: A
authors.lastname: Auvinen
authors.forename: Jukka
authors.initials: J
authors.lastname: Peltola
authors.forename: Anna-Maija
authors.initials: AM
authors.lastname: Haapala
authors.forename: Jani
authors.initials: J
authors.lastname: Raitanen
authors.forename: Jouko
authors.initials: J
authors.lastname: Isojärvi
mesh_terms: D000927:Anticonvulsants / Q000627:therapeutic use; D016022:Case-Control Studies; D015331:Cohort Studies; D016001:Confidence Intervals; D003430:Cross-Sectional Studies; D004827:Epilepsy / Q000097:blood* / Q000188:drug therapy / Q000453:epidemiology / Q000276:immunology; D005260:Female; D006801:Humans; D007070:Immunoglobulin A / Q000097:blood*; D007074:Immunoglobulin G / Q000097:blood*; D007075:Immunoglobulin M / Q000097:blood*; D016014:Linear Models; D008297:Male; D016017:Odds Ratio; D015995:Prevalence
chemical_list: D000927:Anticonvulsants; D007070:Immunoglobulin A; D007074:Immunoglobulin G; D007075:Immunoglobulin M